Targeted delivery of curcumin for treating type 2 diabetes

Maradana, Muralidhara Rao, Thomas, Ranjeny and O'Sullivan, Brendan J. (2013) Targeted delivery of curcumin for treating type 2 diabetes. Molecular Nutrition and Food Research, 57 9: 1550-1556. doi:10.1002/mnfr.201200791


Author Maradana, Muralidhara Rao
Thomas, Ranjeny
O'Sullivan, Brendan J.
Title Targeted delivery of curcumin for treating type 2 diabetes
Journal name Molecular Nutrition and Food Research   Check publisher's open access policy
ISSN 1613-4125
1613-4133
Publication date 2013-01-01
Year available 2013
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1002/mnfr.201200791
Volume 57
Issue 9
Start page 1550
End page 1556
Total pages 7
Place of publication Weinheim, Germany
Publisher Wiley - V C H Verlag GmbH & Co. KGaA
Language eng
Subject 1106 Human Movement and Sports Science
1305 Biotechnology
Abstract Type 2 diabetes is a chronic condition in which cells have reduced insulin signalling, leading to hyperglycemia and long-term complications, including heart, kidney and liver disease. Macrophages activated by dying or stressed cells, induce the transcription factor nuclear factor kappa-B leading to the production of pro-inflammatory cytokines including TNF and IL-6. These inflammatory macrophages in liver and adipose tissue promote insulin resistance, and medications which reduce inflammation and enhance insulin signalling improve glucose control. Curcumin is an anti-oxidant and nuclear factor kappa-B inhibitor derived from turmeric. A number of studies have shown that dietary curcumin reduces inflammation and delays or prevents obesity-induced insulin resistance and associated complications, including atherosclerosis and immune mediate liver disease. Unfortunately dietary curcumin is poorly absorbed by the digestive system and undergoes glucuronidation and excretion rather than being released into the serum and systemically distributed. This confounds understanding of how dietary curcumin exerts its beneficial effects in type 2 diabetes and associated diseases. New improved methods of delivering curcumin are being developed including nanoparticles and lipid/liposome formulations that increase absorption and bioavailability of curcumin. Development and refinement of these technologies will enable cell-directed targeting of curcumin and improved therapeutic outcome.
Keyword Curcumin
Liposomes
Macrophages
NF-κB
Type 2 diabetes
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: Official 2014 Collection
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 29 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 36 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 29 Nov 2013, 05:23:35 EST by System User on behalf of UQ Diamantina Institute